rethinkTHC Search
Menu
Study breakdown

Systematic review found medical cannabis shows promise for fibromyalgia pain but evidence gaps remain

Systematic ReviewModerate evidence
The takeaway

A systematic review of 22 studies found medical cannabis may be safe and effective for fibromyalgia pain, with THC/CBD ratio determining effects on different symptoms, but dosing and long-term data are lacking.

Fibromyalgia patients, rheumatologists, and pain management clinicians.

22 studies reviewed across multiple cannabinoid formulations

What the researchers found

Across 22 studies, medical cannabis (including nabilone, dronabinol, and various THC/CBD ratios) showed analgesic and anti-inflammatory effects in fibromyalgia patients. The THC-to-CBD ratio influenced which symptoms improved most. Studies used products including nabilone, dronabinol, Bedrocan (22.4mg THC), Bediol (13.4mg THC + 17.8mg CBD), and Bedrolite (18.4mg CBD).

Why it matters

Fibromyalgia affects millions and current FDA-approved treatments have limited effectiveness. Cannabis represents a potential alternative, particularly as the opioid crisis makes non-opioid pain options increasingly important.

The numbers in context

22 articles included. Formulations studied: nabilone, dronabinol, Bedrocan (22.4mg THC, <1mg CBD), Bediol (13.4mg THC, 17.8mg CBD), Bedrolite (18.4mg CBD, <1mg THC). THC/CBD ratio influenced symptom-specific effects.

How the study worked

Systematic review following PRISMA guidelines. Searched PubMed, MEDLINE, PubMed Central, and Google Scholar. 22 articles met inclusion criteria after quality assessment. Analyzed the role of cannabis in fibromyalgia treatment across different cannabinoid formulations.

What this study cannot tell us

Heterogeneous study designs across the 22 included studies. Limited data on optimal dosing, treatment duration, adverse effects, and long-term outcomes. Many studies were small or observational.

How to read the evidence

Systematic review with PRISMA methodology, but underlying studies were heterogeneous and often small.

When this study was published

2021 systematic review.

The bigger picture

The finding that different THC/CBD ratios affect different fibromyalgia symptoms suggests that a one-size-fits-all approach to medical cannabis for fibromyalgia is unlikely to work. Personalized formulation selection may be key to optimizing outcomes.

Questions still open

  • What is the optimal THC/CBD ratio for different fibromyalgia symptoms? What are the long-term effects and dependence risks? How does medical cannabis compare to approved fibromyalgia medications in head-to-head trials?

Common questions

Does medical cannabis work for fibromyalgia?
The reviewed evidence suggests it may help with pain and other symptoms, but the evidence base has significant gaps. Different formulations (varying THC/CBD ratios) appear to affect different symptoms.
Which cannabis formulation is best for fibromyalgia?
The review found that the THC/CBD ratio matters, but could not identify a single optimal formulation. Products ranged from THC-dominant to CBD-dominant, each showing different symptom-specific effects.

Read the original research

A Systematic Review of Fibromyalgia and Recent Advancements in Treatment: Is Medicinal Cannabis a New Hope?

Cureus, 13(8), e17332

Citation

Khurshid, Hajra; Qureshi, Israa A; Jahan, Nasrin; Went, Terry R; Sultan, Waleed; Sapkota, Alisha; Alfonso, Michael. (2021). A Systematic Review of Fibromyalgia and Recent Advancements in Treatment: Is Medicinal Cannabis a New Hope?. Cureus, 13(8), e17332. https://doi.org/10.7759/cureus.17332

Explore the wider topic